Follow-On Indications

Candidate & Indication Clinical Stage Conducted
Preclinical Phase 1 Phase 2 Phase 3 Market
REM-001 Cutaneous Metastatic Cancers Other than CMBC (e.g., Lung, Ovarian and Colon)
Preclinical Not Started
Phase 1 Not Started
Phase 2 Not Started
Phase 3 Not Started
Market Not Started

Other Cutaneous Metastatic Cancers

Once progress is made with REM-001 Therapy in cutaneous metastatic breast cancer (CMBC), a number of closely related cancers are targets for further clinical development.

A meta-analysis has shown that approximately 5% of people with internal (non-melanoma, non-lymphatic, non-leukemic) cancers develop cutaneous metastatic tumors in their skin. Based on an estimated incidence of 1,500,000 such internal cancers in the United States, this means that the incidence of such cutaneous metastases is approximately 75,000 with a substantially higher prevalence, given the fact that individuals often live with metastatic cancer for years. Regardless of the primary source of the cancer, these cutaneous metastatic tumors often begin as small skin nodules but, as the cancer spreads, more nodules form and can eventually cover large areas of skin. With progression, the tumor field generally becomes more painful as tumors may grow larger and more numerous, become infected, ulcerate, bleed and carry a strong odor. Some common cutaneous metastatic cancers besides breast are lung, ovarian and colon cancer. As with CMBC, cutaneous metastatic lung cancer patients develop these tumor nodules on their chest, while with ovarian and colon cancer the tumors most frequently develop on the abdomen. Another cancer that frequently forms metastatic cutaneous tumors is metastatic melanoma. When it metastasizes, melanoma often forms fields of cutaneous tumors that behave in a very similar manner to the other cutaneous metastatic cancers. Part of our goal is to treat these cutaneous tumors as early as possible to either cause them to be locally eliminated or to slow their growth sufficiently to reduce their late stage development.

More about Photodynamic Therapy